Galecto Inc (NAS:GLTO)
$ 0.6051 0.011 (1.81%) Market Cap: 16.41 Mil Enterprise Value: -10.61 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 38/100

Galecto Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 11:00AM GMT
Release Date Price: $2.54 (-2.31%)
Thomas Year
H.C. Wainwright & Co.

Hello, everyone. Welcome to the H.C. Wainwright 24th Annual Global Investment Conference. This is Thomas [Year] from H.C. Wainwright.

For our next presentation, we have Hans Schambye. He's the CEO of Galecto, a clinical stage company developing novel treatments for cancer and fibrosis.

Hans, very happy to have you with us. Please go ahead.

Hans Schambye
Galecto, Inc. - CEO

Thanks a lot, Thomas. We're very happy to be here. Hello, everybody. I'm happy to introduce you to Galecto.

So I will be making forward-looking statements, and you can find these on our homepage. Galecto is well capitalized, clinical stage biotech. We have very near-term catalysts. We have announced that we will be reporting data this [quarter].

We have a platform developing [single] molecule-based pharmaceuticals for the treatment of oncological and fibrotic diseases. We're working on two different proteins: galectin-3 and LOXL2, (technical difficulty) both been shown to play critical roles in the overlapping

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot